Mirna Therapeutics Inc. (MIRN) Given Hold Rating at HC Wainwright
Several other equities analysts have also recently weighed in on the company. Citigroup Inc. reduced their price target on Mirna Therapeutics from $4.50 to $2.00 and set a neutral rating for the company in a research report on Thursday, September 22nd. Leerink Swann restated a neutral rating and set a $1.50 target price (down from $4.00) on shares of Mirna Therapeutics in a research report on Wednesday, September 21st. Oppenheimer Holdings Inc. cut Mirna Therapeutics from an outperform rating to a market perform rating in a research report on Wednesday, September 21st. Cantor Fitzgerald cut Mirna Therapeutics from a buy rating to a hold rating and reduced their target price for the stock from $14.00 to $2.00 in a research report on Wednesday, September 21st. Finally, Zacks Investment Research upgraded Mirna Therapeutics from a hold rating to a buy rating and set a $2.75 target price for the company in a research report on Wednesday, September 7th. Six investment analysts have rated the stock with a hold rating, The company currently has an average rating of Hold and an average target price of $3.88.
Shares of Mirna Therapeutics (NASDAQ:MIRN) traded down 0.336% during trading on Tuesday, hitting $1.186. The stock had a trading volume of 32,092 shares. The company’s market capitalization is $24.71 million. The firm has a 50-day moving average price of $1.55 and a 200 day moving average price of $3.27. Mirna Therapeutics has a 52 week low of $1.12 and a 52 week high of $11.01.
About Mirna Therapeutics
Mirna Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response.
Receive News & Stock Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related stocks with our FREE daily email newsletter.